National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Radium-223 (Xofigo®)

Radium-223 (Xofigo®) is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.

Rapid Review

Commenced Completed Outcome
28/11/2013 23/12/2013 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/04/2014  12/12/2014 Reimbursement Not Recommended

The NCPE does not recommend reimbursement of radium-223 at the submitted price .


December 2015

The HSE has approved reimbursement following confidential price negotiations.